News | Stereotactic Body Radiation Therapy (SBRT) | July 05, 2017

Surgery and High-Dose SBRT Radiation Can Be Combined to Treat Kidney Cancer

First clinical study to show benefit of surgery following SBRT, and to demonstrate that SBRT stimulates immune system

Surgery and High-Dose SBRT Radiation Can Be Combined to Treat Kidney Cancer

July 5, 2017 — A new study from Roswell Park Cancer Institute reporting the findings of the first clinical trial to evaluate the immune effects of high-dose radiation therapy followed by surgery in patients with advanced kidney cancer may also set the stage for combination treatments with immunotherapy. The research, published in Clinical Cancer Research, a journal of the American Association for Cancer Research (AACR), shows that nephrectomy can be effectively paired with stereotactic body radiation therapy (SBRT), and also provides strong evidence that immunotherapy may be an effective third element to incorporate into this combination therapy strategy.

In a pilot clinical study, 14 patients with metastatic renal cell carcinoma (mRCC) were treated with SBRT in a single administration (fraction) followed four weeks later by cytoreductive nephrectomy, or surgery to remove or reduce the size of their tumors. The team set out to assess the safety and feasibility of this approach and analyze the immunological impact of high-dose radiation. Based on their preliminary studies in the lab, the team monitored patients’ tumors for expression of immunomodulatory molecules and tumor-associated antigens. 

“We saw a significant increase in calreticulin and other molecules that stimulate T cells,” said the paper’s first author, Anurag Singh, M.D., professor of oncology and director of radiation research with the Department of Radiation Medicine at Roswell Park. “This suggests that it may be possible to improve the effectiveness of immunotherapies by first priming the pump with high-dose radiation.” 

The authors include a contributor from the Department of Radiation Oncology at the Medical University of South Carolina.

Findings from this research will also be presented at the American Society for Radiation Oncology (ASTRO) Annual Meeting, Sept. 24-27 in San Diego, where Singh will receive a Basic/Translational Science Abstract Award for his role in this work.

The research was supported by grants from the National Center for Advancing Translational Sciences (project no. UL1TR001412), National Cancer Institute (project nos. P30CA016056 and R01CA140622), the Sklarow Foundation, Elsa Kreiner Memorial Fund, Fraternal Order of Eagles and RPCI Friends of Urology.

For more information: www.clincancerres.aacrjournals.org

Related Content

Turkish Hospital Begins MR-Guided Radiation Therapy With Viewray MRIdian Linac
News | Image Guided Radiation Therapy (IGRT) | September 21, 2018
ViewRay Inc. announced that Acibadem Maslak Hospital in Istanbul, Turkey has begun treating patients with ViewRay's...
Machine Learning IDs Markers to Help Predict Alzheimer's

Neurologists use structural and diffusion magnetic resonance imaging (MRI) to identify changes in brain tissue (both gray and white matter) that are characteristic of Alzheimer's disease and other forms of dementia. The MRI images are analyzed using morphometry and tractography techniques, which detect changes in the shape and dimensions of the brain and in the tissue microstructure, respectively. In this example, the images show the normal brain of an elderly patient. Image courtesy of Jiook Cha.

News | Neuro Imaging | September 20, 2018
New research has shown a combination of two different modes of magnetic resonance imaging (MRI), computer-based...
Amar Kishan, M.D.

Amar Kishan, M.D.

News | Prostate Cancer | September 11, 2018
UCLA researchers have discovered that a combination of high doses of...
Videos | Radiation Therapy | September 07, 2018
A discussion with Ehsan Samei, Ph.D., DABR, FAAPM, FSPIE, director of the Duke University Clinical Imaging Physics Gr
Boston Scientific to Acquire Augmenix Inc.
News | Patient Positioning Radiation Therapy | September 07, 2018
Boston Scientific has entered into a definitive agreement to acquire Augmenix Inc., a privately-held company which has...
PET Imaging Agent Predicts Brain Tau Pathology, Alzheimer's Diagnosis
News | PET Imaging | September 05, 2018
Eli Lilly and Co. and Avid Radiopharmaceuticals Inc. announced a Phase 3 study of positron emission tomography (PET)...
Check-Cap Announces Interim Results of European Study of C-Scan System Version 3
News | Colonoscopy Systems | September 04, 2018
Check-Cap Ltd. announced the interim results for its post-CE approval study of the C-Scan system Version 3, an...
Brain Iron Levels May Predict Multiple Sclerosis Disabilities
News | Neuro Imaging | August 31, 2018
A new, highly accurate magnetic resonance imaging (MRI) technique can monitor iron levels in the brains of multiple...
Study Finds Multiple Sclerosis Drug Slows Brain Shrinkage

An NIH-funded clinical trial suggested that the anti-inflammatory drug ibudilast may slow brain shrinkage caused by progressive MS. Image courtesy of Robert J. Fox, M.D., Cleveland Clinic.

News | Neuro Imaging | August 30, 2018
August 30, 2018 — Results from a clinical...
Non-Canonical Strategy May Improve Cancer Radiotherapy
News | Radiation Therapy | August 29, 2018
August 29, 2018 — Although the success or failure of...